Unicycive Therapeutics, Inc. announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) has completed review of the Clinical Trial Application (CTA) and has issued a notice of acceptance for UNI-494 first-in-human Phase 1 study in healthy volunteers.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6604 USD | +0.82% | -15.33% | -23.89% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.89% | 24.84M | |
+48.54% | 56.61B | |
+37.15% | 39.25B | |
-6.02% | 39.62B | |
-6.90% | 28.28B | |
+12.97% | 26.44B | |
-16.91% | 20.12B | |
+31.71% | 12.48B | |
+28.18% | 12.51B | |
+0.38% | 12.2B |
- Stock Market
- Equities
- UNCY Stock
- News Unicycive Therapeutics, Inc.
- Unicycive Therapeutics, Inc. Announces Medicines and Healthcare Products Regulatory Agency in the United Kingdom Complete Review of the Clinical Trial Application and Issue A Notice of Acceptance for UNI-494 First-In-Human Phase 1